Targeting the LMP1‐ALIX axis in EBV + nasopharyngeal carcinoma inhibits immunosuppressive small extracellular vesicle secretion and boosts anti‐tumor immunity
Cancer Communications · 2024-12 · 44 (12) · 1391-1413
DOI: 10.1002/cac2.12619 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Communications, online erschienen am 14.10.2024. Verfasst von Fajian He und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospit…. Hauptthemen laut MEDLINE: Viral Matrix Proteins, Nasopharyngeal Carcinoma, Extracellular Vesicles, Herpesvirus 4, Human. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Health Commission of Hubei Province Medical Leading Talent Project, and Translational Medicine and Interdisciplinary Research Joint Fund of Zhongnan Hospital o…, Key Research & Development Project of Hubei Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Immunotherapy has revolutionized the therapeutical regimen for nasopharyngeal carcinoma (NPC), yet its response rate remains insufficient. Programmed death‐ligand 1 (PD‐L1) on small extracellular vesicles (sEVs) mediates local and peripheral immunosuppression in tumors, and the mechanism of PD‐L1 loading into these vesicles is garnering increasing attention. Latent membrane protein 1 (LMP1), a key viral oncoprotein expressed in Epstein‐Barr virus (EBV)‐positive NPC, contributes to remodeling the tumor microenvironment. However, the precise mechanisms by which LMP1 modulates tumor immunity in NPC remain unclear. Here, we aimed to investigate the roles and regulatory mechanisms of LMP1 and sEV PD‐L1 in NPC immune evasion.
Methods
We analyzed the impact of LMP1 on tumor‐infiltrating lymphocyte abundance in NPC tissues and humanized tumor‐bearing mouse models using multiplex immunofluorescence (mIF) and flow cytometry, respectively. Transmission electron microscopy and nanoparticle tracking analysis were employed to characterize sEVs. Immunoprecipitation‐mass spectrometry was utilized to identify proteins interacting with LMP1. The regulatory effects of sEVs on tumor microenvironment were assessed by monitoring CD8 + T cell proliferation and interferon‐γ (IFN‐γ) expression via flow cytometry. Furthermore, the expression patterns of LMP1 and downstream regulators in NPC were analyzed using mIF and survival analysis.
Results
High LMP1 expression in NPC patient specimens and mouse models was associated with restricted infiltration of CD8 + T cells. Additionally, LMP1 promoted sEV PD‐L1 secretion, leading to inhibition of CD8 + T cell viability and IFN‐γ expression in vitro. Mechanistically, LMP1 recruited apoptosis‐linked gene 2‐interacting protein X (ALIX) through its intracellular domain and bound PD‐L1 through its transmembrane domain, thereby facilitating the loading of PD‐L1 into ALIX‐dependent sEVs. Disruption of ALIX diminished LMP1‐induced sEV PD‐L1 secretion and enhanced the anti‐tumor immunity of CD8 + T cells both in vitro and in vivo. Moreover, increased expression levels of LMP1 and ALIX were positively correlated with enhanced immunosuppressive features and worse prognostic outcomes in NPC patients.
Conclusion
Our findings uncovered the mechanism by which LMP1 interacts with ALIX and PD‐L1 to form a trimolecular complex, facilitating PD‐L1 loading into ALIX‐dependent sEV secretion pathway, ultimately inhibiting the anti‐tumor immune response in NPC. This highlights a novel target and prognostic marker for NPC immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, P. R. China.
- Tumor Precision Diagnosis and Treatment Technology and Translational Medicine, Hubei Engineering Research Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, P. R. China.
- Department of Radiotherapy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China.
- Wuhan Research Center for Infectious Diseases and Cancer, Chinese Academy of Medical Sciences, Wuhan, Hubei, P. R. China.
ORCID-Profile: Qiuji Wu, Conghua Xie
Förderung
- Health Commission of Hubei Province Medical Leading Talent Project, and Translational Medicine and Interdisciplinary Research Joint Fund of Zhongnan Hospital o…
- Key Research & Development Project of Hubei Province
- National Natural Science Foundation of China
- Research Projects of Biomedical Center of Hubei Cancer Hospital
Zitieren
APA
He, F., Gong, Y., Tao, G., Zhang, J., Wu, Q., Tan, Y., Cheng, Y., Wang, C., Yang, J., Han, L., Wang, Z., Gao, Y., He, J., Bai, R., Sun, P., Yu, X., Zhou, Y., & Xie, C. (2024). Targeting the LMP1‐ALIX axis in EBV + nasopharyngeal carcinoma inhibits immunosuppressive small extracellular vesicle secretion and boosts anti‐tumor immunity. Cancer Communications, 44(12), 1391-1413. https://doi.org/10.1002/cac2.12619
Vancouver
He F, Gong Y, Tao G, Zhang J, Wu Q, Tan Y, et al. Targeting the LMP1‐ALIX axis in EBV + nasopharyngeal carcinoma inhibits immunosuppressive small extracellular vesicle secretion and boosts anti‐tumor immunity. Cancer Communications. 2024;44(12):1391-1413. doi:10.1002/cac2.12619
BibTeX
@article{He2024,
author = {He, Fajian and Gong, Yan and Tao, Gan and Zhang, Jianguo and Wu, Qiuji and Tan, Yushuang and Cheng, Yajie and Wang, Chunsheng and Yang, Jinru and Han, Linzhi and Wang, Zhihao and Gao, Yanping and He, Jingyi and Bai, Rui and Sun, Peikai and Yu, Xiaoyan and Zhou, Yajuan and Xie, Conghua},
title = {Targeting the LMP1‐ALIX axis in EBV + nasopharyngeal carcinoma inhibits immunosuppressive small extracellular vesicle secretion and boosts anti‐tumor immunity},
journal = {Cancer Communications},
year = {2024},
volume = {44},
number = {12},
pages = {1391--1413},
doi = {10.1002/cac2.12619}
}
EUVIMED